ProNAi Therapeutics, Inc. Reports Anti-Tumor Activity From Ongoing Phase II Clinical Study Of PNT2258, A Novel BCL2-Inhibitor, At American Society of Hematology Annual Meeting

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

ProNAi Therapeutics, Inc., a leader in developing nucleic acid therapeutics, presented safety and efficacy data from its ongoing Phase II study yesterday at the 55th Annual Meeting of the American Society for Hematology (ASH) in New Orleans, Louisiana. Phase II findings on the company’s first-in-class BCL2 targeted IV drug were presented in an oral session on Novel Therapies for Lymphoma, titled “The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active In Patients With Relapsed Or Refractory Non-Hodgkin’s Lymphoma.” PNT2258’s unique mechanism of action targets the BCL2 gene directly, rather than the BCL2 protein, to inhibit cancer cell proliferation, drive cell death (apoptosis) and minimize off-target effects.

Help employers find you! Check out all the jobs and post your resume.

Back to news